Richard Lock

Has grant

Head

Children's Cancer Institute Australia

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Richard Lock is the Head of the Children's Cancer Institute Australia. His research primarily focuses on childhood leukemia, with recent articles addressing the treatment of high-risk B-cell acute lymphoblastic leukemia and the mechanisms underlying chemoresistance in T-cell precursor acute lymphoblastic leukemia. In addition, he studies the role of immune-deficient models in leukemia progression and strategies to inhibit adverse effects in leukemia treatments.

Recent Grants

Grant: Close

'Multi-Coloured' Tracers for Magnetic Particle Imaging

Open Date: 2020-01-01

Close Date: 2022-12-31

Grant: Close

Molecular Characterisation of Relapse-Initiating Acute Lymphoblastic Leukaemia Cells for Targeted Therapy

Open Date: 2019-01-01

Close Date: 2021-01-01

Grant: Close

Generating patient derived MDS xenografts for pre-clinical drug testing

Open Date: 2019-01-01

Close Date: 2023-12-01

Grant: Close

Improving the treatment of childhood cancer

Open Date: 2019-01-01

Close Date:

Grant: Close

Improving the outcome for childhood leukaemia

Open Date: 2017-09-01

Close Date: 2020-12-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Sara Mohamed

Conjoint Associate Lecturer

University of New South Wales Science

AUSTRALIA

Richard Lock

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia

Immune‐deficient MISTRG mice support expansion of leukaemia‐initiating cells in xenograft models of paediatric acute myeloid leukaemia

Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia: ACUTE LYMPHOBLASTIC LEUKEMIA

Inhibition of the NLRP3 inflammasome using MCC950 reduces vincristine‐induced adverse effects in an acute lymphoblastic leukemia patient‐derived xenograft model

Polyamine depletion limits progression of acute leukaemia

The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia

ETV6::ACSL6 translocation-driven super-enhancer activation leads to eosinophilia in acute lymphoblastic leukemia through IL-3 overexpression

3049 – TARGETING BONE MARROW MICROENVIRONMENT FOR TREATMENT OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Precision-guided treatment in high-risk pediatric cancers

FDA-approved disulfiram as a novel treatment for aggressive leukemia

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts

An antibody fragment-decorated liposomal conjugate targets Philadelphia-like acute lymphoblastic leukemia

TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells

PU.1 eviction at lymphocyte-specific chromatin domains mediates glucocorticoid response in acute lymphoblastic leukemia

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

Lessons learned from 20 years of preclinical testing in pediatric cancers

Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia

High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer

Small zinc doped iron oxide tracers for magnetic particle imaging

In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts

Collaborators (17)

Sara Mohamed

Benjamin Mullin

Hansen Kosasih

Gabor Tax

Russell Pickford

Ernest Moles

Jinbo Yuan

Nicholas Gottardo

Yizhou Huang

Owen Duncan

Maria Kavallaris

Laurence C Cheung

Christopher Smith

Vanessa Tyrrell

Chelsea Mayoh

Lucy Gloag

Rishi Kotecha

Make your next move.